Tofacitinib with Concomitant Therapy for Vitiligo: protocol for a phase II randomized clinical trial (Preprint)
UNSTRUCTURED Vitiligo is the most common acquired skin depigmentation disorder that affects about 35 million people worldwide. This debilitating disease causes autoimmune destruction of the epidermal melanocytes, forming macules and patches of hypopigmented skin, which causes considerable stigma and a decrease in the quality of life in affected individuals. Narrowband UVB (NB-UVB) is the preferred treatment right now, alone or in combination with immunomodulator drugs. It is not 100% effective and has many adverse effects, as noted in the literature previously. The addition of topical Tofacitinib to the already present therapy has the potential to be a novel treatment with a high level of efficacy for vitiligo. This can significantly improve the quality of life in the millions of people suffering from vitiligo worldwide.